Davita Inc vs T1 Energy Inc. Common Stock — how do they compare? Davita Inc trades at $180 (market cap $11.62B), while T1 Energy Inc. Common Stock trades at $2.81 (market cap $946.42M). The key difference: Davita Inc is far larger — about 12.3× T1 Energy Inc. Common Stock's market cap, and Davita Inc is trading nearer its 52-week high, T1 Energy Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and T1 Energy Inc. Common Stock for 0 Days on average.
| DVA | TE | |
|---|---|---|
Market Cap | $11.62B | $946.42M |
Volume | 400,903 | 12,898,774 |
Sector | Health | Industrials |
52-Week High | $240.96 | $12.04 |
52-Week Low | $103.87 | $2.72 |
Typical Hold Time | 114 Days | 0 Days |
Enterprise Value | $24.33B | $1.72B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $180.70, down 0.59% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 15.43 P/E ratio. The stock shows bullish technical signals with moving averages supporting upward momentum, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents compelling value with analyst consensus target of $235.67 offering 30% upside potential, supported by Warren Buffett's substantial ownership. Key risks include rising debt-to-asset ratio reaching 65.55% and regulatory pressures in healthcare. The combination of earnings momentum, institutional support, and reasonable valuation creates favorable investment conditions despite margin compression concerns.
T1 Energy (TE) trades at $3.16, down 1.56% today, reflecting ongoing investor caution despite a mixed earnings history. The company shows significant revenue growth from $755M in 2025 to $997M in 2026 but remains deeply unprofitable with a -38.49% net margin. Recent news highlights strategic moves toward vertical integration in solar manufacturing and energy storage, including the G2_Austin facility development and new supply agreements, which are central to its growth narrative.
The investment case hinges on execution of vertical integration and policy tailwinds, offering substantial upside to the $8 consensus target, but high execution risk, persistent losses, and regulatory scrutiny present clear dangers. Analyst sentiment is mixed with a Moderate Buy rating, yet the stock's viability depends heavily on future profitability improvements from 2027 onward.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →T1 Energy Inc. manufactures photovoltaic solar modules and cells in US, operating a solar manufacturing facility in Texas acquired from Trina Solar. The company was formerly known as FREYR Battery before rebranding as T1 Energy in 2025 and changing its NYSE ticker from FREY to TE.
Read more on TE →